Pre-made Bafisontamab benchmark antibody ( Whole mAb, anti-EGFR;MET therapeutic antibody, Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;AUTS9/DFNB97/HGFR/RCCP2/c-Met Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Bafisontamab biosimilar, Whole mAb, Anti-EGFR;MET Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-656-1mg	1mg	Inquiry
GMP-Bios-ab-656-10mg	10mg	Inquiry
GMP-Bios-ab-656-100mg	100mg	Inquiry
GMP-Bios-ab-656-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Bafisontamab biosimilar, Whole mAb, Anti-EGFR;MET Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody
INN Name	Bafisontamab
Target	EGFR;MET
Format	Bispecific Mixed mAb and Fab
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1;na
VD LC	Kappa;Kappa
Highest_Clin_Trial (Jan '20)	Phase-I/II
Est. Status	Active
100% SI Structure	5sx4:HL/5sx5:JK;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2021
Year Recommended	na
Companies	EpimAb Biotherapeutics
Conditions Approved	na
Conditions Active	Non-small cell lung cancer;Solid tumours
Conditions Discontinued	na
Development Tech	na